Table 4 Cyberknife treatment characteristics (by patients)
Patients | Hepatic (n = 75) | Lung (n = 15) | All Patients (n = 90) |
|---|---|---|---|
Dose per fractions, n (%) | |||
6 | 0 | 1 | 1 (1,1%) |
9 | 2 | 0 | 2 (2,2%° |
10 | 31 (41%) | 1 | 32 (35,6%) |
12 | 3 | 0 | 3 (3,3%) |
13 | 2 | 0 | 2 (2,2%) |
15 | 37 (49%) | 11 (73%) | 48 (53,3%) |
20 | 0 | 2 | 2 (2,2%) |
Total dose, n (%) | |||
27 | 1 | 0 | 1,1% |
30 | 2 | 0 | 2,2% |
36 | 3 | 1 | 4,4% |
39 | 2 | 0 | 2,2% |
40 | 29 (39%) | 1 | 30 (33,3%) |
45 | 37 (49%) | 11 (73%) | 48 (53,3%) |
54 | 1 | 0 | 1,1% |
60 | 0 | 2 | 2,2% |
Treatment duration, median (range) | 8 days(3 – 22) | ||